Traws Pharma inc (TRAW) - News Archive

Traws Pharma in Transition: Charting a Course through Financial Struggles and Promising InnovationsNEWTOWN, Pa.—In a surprising move, Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company at the...

: Traws Pharma, Inc. has unveiled significant progress in its antiviral bird flu program, announcing positive topline results from a pivotal study utilizing tivoxavir marboxil (TXM). This investigational oral small mole...

In a rapidly evolving biopharmaceutical sector, Traws Pharma, Inc. has emerged as a notable player, particularly within the sphere of oral therapeutics for respiratory viral diseases. The company, headquartered in Newto...

Traws Pharma, a rising biopharmaceutical company, has recently released encouraging Phase 1 data for its investigational antiviral drug, Tivoxavir Marboxil. The novel agent, designed for single-dose treatment or prevent...

: The pharmaceutical landscape has been profoundly impacted by the emergence of COVID-19, necessitating rapid innovation in antiviral therapies. Traws Pharma’s recent announcement regarding the topline results from a Ph...